On Monday, April 22nd at 3pm ET, we hosted a special webinar with NephCure highlighting the latest in nephrotic syndrome research and kidney genomics!

Join Dr. Matthew Sampson, a Pediatric Nephrologist at Boston Children's Hospital and Harvard Medical School, as he shares insights from his work in the field, discoveries, and collaborative efforts aimed at improving care for patients and families affected by rare kidney disease.

Don’t miss this opportunity to delve into the world of kidney genomics and nephrotic syndrome research.

We're headed to the National Kidney Foundation Clinicals in Austin, Texas where Michelle McNulty, MS will be speaking alongside Drs. Rasheed Gbadegesin and Jeffrey Kopp about "APOL1 Mediated Kidney Disease: What Does the Future Hold"? The session is happening over lunch on April 13 at 12 pm in Ballroom A, Austin Convention Center.

Can't make it in person? Tune into the #NKFClinicals livestream.

About the session:

APOL1-mediated kidney disease (AMKD) is a kidney disorder caused by certain apolipoprotein L1 (APOL1) genetic mutations. This genetic disease can lead to renal cell injury and damage to the glomeruli, resulting in proteinuria and progression to end stage kidney disease. This program will address APOL1 epidemiology and potential mechanisms of AMKD, as well as implications of genetic ancestry and approaches to testing, followed by a discussion of current and emerging therapies for AMKD.

On February 28th, our lab lit up in green, blue, pink, and purple in solidarity and support for those affected by rare diseases. Rare Disease Day leads the efforts in raising awareness and generating change for the 300 million people living with a rare disease worldwide.

As a lab that studies pediatric nephrotic syndrome, a rare kidney disease, we believe in creating equitable access to healthcare. We hope our work inspires the next generation of researchers to study and make discoveries of the treatments and even cures of rare diseases.

We're closing another year of outstanding accomplishments and challenges overcome with the help of our amazing team. We can't wait to continue our work on nephrotic syndrome in 2023 and in many more years to come.

Thank you all for your support. We are appreciative of each and every one of you.

At the Sampson Lab, we love our community and we want to keep you updated on all the great things our team is doing. We’re excited to announce that in addition to news features on our website and Matt’s @kidneyomicsamps Twitter, we are also launching three new social media accounts on Facebook, Instagram, and Twitter! We plan on sharing educational information about the kidney, highlights of our team members, and updates on our research and the BIGKiDs study.

We hope you consider joining us on your preferred social media and encourage you to share this with your friends, family, and co-workers. We look forward to connecting with you and seeing our community grow!

Facebook | Instagram | Twitter